Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.

Kantor D, Chancellor MB, Snell CW, Henney Iii HR, Rabinowicz AL.

Postgrad Med. 2015 Feb;127(2):218-22. doi: 10.1080/00325481.2015.1000229. Epub 2015 Jan 6.

PMID:
25560174
2.

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K.

BMC Neurol. 2014 Nov 26;14(1):220. [Epub ahead of print]

3.

Novel therapeutics in multiple sclerosis management: clinical applications.

Leist T, Hunter SF, Kantor D, Markowitz C.

Am J Med. 2014 Jan;127(1):S2. doi: 10.1016/j.amjmed.2013.06.015.

PMID:
24384114
4.

PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.

Brooks BR, Crumpacker D, Fellus J, Kantor D, Kaye RE.

PLoS One. 2013 Aug 21;8(8):e72232. doi: 10.1371/journal.pone.0072232. eCollection 2013.

5.

The impact of migraine on school performance.

Kantor D.

Neurology. 2012 Oct 30;79(18):e168-9. doi: 10.1212/WNL.0b013e3182745a97. No abstract available.

PMID:
23109661
6.

Cervical epidural blood patch for low CSF pressure headaches.

Kantor D, Silberstein SD.

Neurology. 2005 Oct 11;65(7):1138. No abstract available.

PMID:
16217080
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk